Abstract
Charcot–Marie–Tooth disease (CMT) is the most common form of hereditary neuropathy. With the advent of new molecular techniques like NGS, the clinical and genetic spectrum of CMT has been greatly expanded .Our aim is to review the recent research advances in CMT in the last five years (2012-2016), including an update on classification and genetic spectrum, additions to the algorithm for CMT diagnosis and the developments of new animal models and biomarkers. We will also discuss the progress in potential treatments for CMT. Though there is still no effective therapy to date, a number of large-scales new therapeutic trials such as PXT3003 may give hopes for curative therapies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
